On October 7, 2025, IGC Pharma, Inc. announced in‑vitro findings for its low‑molecular‑weight compound IGC‑1C, a candidate designed to target tau protein liquid‑liquid phase separation (LLPS). The data confirm that IGC‑1C acts as a modulator of LLPS, a critical pathway implicated in the earliest stages of Alzheimer’s disease and related tauopathies.
The study demonstrates high binding affinity of IGC‑1C to tau protein, supporting its potential to disrupt the formation of neurotoxic tangles. This mechanistic insight positions IGC‑1C as a promising disease‑modifying agent distinct from the company’s current agitation‑focused candidate IGC‑AD1.
The announcement marks the first experimental evidence for IGC‑1C and represents a significant milestone in IGC Pharma’s strategy to develop novel therapeutics for Alzheimer’s disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.